Related Experiment Video

Updated: Jun 12, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Peptide-based Antifungal Therapies against Emerging Infections

A Matejuk1, Q Leng, M D Begum

  • 1Department of Pathology, University of Maryland Baltimore, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA.

Drugs of the Future
|May 25, 2010
PubMed

Insights

Antifungal peptides offer a promising new strategy against drug-resistant fungal infections, especially in immunocompromised patients. Research is advancing peptide-based therapies for challenging mycotic infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Biotechnology

Background:

  • Acquired drug resistance in mycotic infections presents a growing global health challenge.
  • Opportunistic fungal infections pose significant risks to immunocompromised individuals, including those with AIDS, cancer, and transplant recipients.
  • Increasing mortality rates from invasive mycosis necessitate the development of novel antifungal agents due to widespread antibiotic resistance.

Purpose of the Study:

  • To review recent advancements in peptide therapy for opportunistic fungal infections.
  • To highlight the potential of antifungal peptides as novel therapeutic agents.
  • To discuss the mechanisms and therapeutic utility of plant and animal-derived peptides.

Main Methods:

  • Review of current scientific literature on antifungal peptides.
  • Analysis of recent progress in protein engineering and solid-phase synthesis techniques.
  • Evaluation of the efficacy and toxicity profiles of selected antifungal peptides.

Main Results:

  • Antifungal peptides, found in plants and animals, show significant potential as therapeutic agents.
  • Advances in synthesis and engineering enable the development of peptides with specific targets or multifunctional actions.
  • Selected peptides demonstrate efficient antifungal activity with acceptable toxicity profiles.

Conclusions:

  • Peptide therapy represents a promising avenue for combating drug-resistant fungal infections.
  • Further research and development in antifungal peptides are crucial for addressing therapeutic challenges in immunocompromised populations.
  • The utility of engineered peptides offers hope for improved treatment outcomes in invasive mycosis.

More Related Videos

Production and Testing of Antimicrobial Peptides and Their Mimics10:35

Production and Testing of Antimicrobial Peptides and Their Mimics

Published on: April 10, 2026

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...